In one case report, a T790M-negative NSCLC patient with exon 19 deletion in EGFR (19del) was successfully rechallenged with osimertinib following acquired resistance to initial gefitinib and second-line Osimertinib (49). Here, EGFR is linked to non-small cell lung carcinoma.